Peey-Sei Kok

6PUBLICATIONS
28CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 21, 2024
Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis.

Angelina Tjokrowidjaja, Peey-Sei Kok, Yoland C Antill

|Jan 11, 2024
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials.

Rachel Woodford, Deborah Zhou, Peey-Sei Kok

|Jan 08, 2023
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).

Deborah Smith, Kristy P Robledo, Sonia Yip

|Jan 26, 2022
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.

Peey Sei Kok, Patrick M Forde, Brett Hughes

|Jan 05, 2022
The validity of progression-free survival 2 as a surrogate trial end point for overall survival.

Rachel G Woodford, Deborah D-X Zhou, Peey-Sei Kok

|Jul 23, 2019
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.

Peey Sei Kok, Philip Beale, Rachel L O'Connell

Pageof 1

Frequent Collaborators

3 joint publications

Yoland C Antill

3 joint publications

Michael L Friedlander

2 joint publications

Ian Marschner

2 joint publications

Chee Khoon Lee